secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001140361-25-033541
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Ionis reports positive Phase 3 results for olezarsen in sHTG: 72% triglyceride drop, 85% pancreatitis reduction
--------------------------------------------------------------------------------

- Olezarsen achieved 72% placebo-adjusted mean reduction in fasting triglycerides in Phase 3 CORE study (p<0.0001)
- Olezarsen reduced acute pancreatitis events by 85% (p=0.0002) in pooled analysis of CORE and CORE2 studies
- Over 90% of patients from CORE/CORE2 enrolled in open-label extension study
- Ionis plans to submit sNDA to FDA for olezarsen in sHTG by end of year

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125033541/0001140361-25-033541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125033541/ef20054942_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-033541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer